Business
Conagra is a branded food company with U.S. retail, foodservice, and international operations. Its brands include Birds Eye, Duncan Hines, Healthy Choice, Marie Callender's, Reddi-wip, Slim Jim, and Angie's Boomchickapop.
Conagra's FY2025 was not a clean turnaround: revenue -3.6% and FCF -20.0%, even as net income rebounded from a weak FY2024 base.
The read at a glance✓ Audited against SEC data
- Growth — Revenue -3.6% to $11.61BWatch
- Profitability — Net income +231.9% to $1.15BOK
- Cash quality — FCF -20.0% to $1.30BWatch
- Margins — Gross margin -180 bpsWatch
- Balance sheet — Debt -3.3%; equity +5.8%OK
- Insiders — 3 buys / 1 sale; $796K boughtOK
Where the revenue comes from
Fiscal 2025, as CONAGRA BRANDS INC. reports it. History and quarterly detail are in the app.
- Grocery And Snacks$4.9B
- Refrigerated And Frozen$4.7B
- Foodservice$1.1B
- International$956.5M
Leadership changes
From CONAGRA BRANDS INC.'s own filings, the day they're filed.
- Melissa Napier · President · appointmenteff. 2025-10-02
- William Eric Johnson · President · appointmenteff. 2023-07-29
- Robert Wise · President · departureeff. 2023-07-29
Latest filings
- 8-K · Company announcement2026-07-28
- 8-K · Company announcement2026-07-28
- 10-K · Annual report2026-07-15
- 8-K · Company announcement2026-07-15
- 8-K · Company announcement2026-06-23
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CONAGRA BRANDS INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.